On the other hand, there was no absolute correlation with mutational or phospho-protein markers of BRAF/MEK, RAS, or phosphoinositide 3-kinase (PI3K) activity to MEK inhibitor response in large tumor cell panels of diverse cancer types [2]. Here, MAP2K7 is linked to cancer.